Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Butamirate Citrate Syrup vs. Sinecod in Healthy Adults
NCT05182047Phase 1Withdrawn
- Sponsor
- McNeil Laboratories
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of butamirate in cough (2 arms), sponsored by McNeil Laboratories. Primary endpoints: Maximum Observed Plasma Concentration of 2-phenylbuturic Acid and Area Under the Concentration Versus Time Curve (AUC [tau]). Planned start Mar 2022; status: withdrawn.
02
Drugs
butamirate
03
Conditions
cough
Beyond the preview
Go deeper on NCT05182047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182047.